Antibodies for bioanalysis and drug monitoring of obinutuzumab

Develop highly selective and sensitive PK and ADA assays for the humanized antibody drug obinutuzumab (Gazyvaro) using our range of ready-made anti-idiotypic antibodies.

  • Inhibitory antibodies specific to obinutuzumab
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch-to-batch consistency
  • Nonanimal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Obinutuzumab.

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Obinutuzumab Inhibitory

Type 1

HCA403

AbD50319ia

hIgG1

0.6

ADA assay

Order HCA403

HCA404

AbD50514ia

hIgG1

1

ADA assay

Order HCA404

HCA405

AbD50104ia

hIgG1

16

ADA assay

Order HCA405

TZA048

AbD51167ad

Fab-F-Spy2-H1

< 0.01

PK bridging ELISA (capture)

Order TZA048

TZA049

AbD51296ad

Fab-F-Spy2-H1

0.3

PK bridging ELISA (detection)

Order TZA049

TZA049P

AbD51296pap

Fab2-FH-X22-HRP2

0.3

PK bridging ELISA (detection)

Order TZA049P

* Affinity measured in the monovalent Fab format
1 Fab-F-Spy2-H = Monovalent Fab antibody with (F) DYKDDDDK, (Spy2) SpyTag version 2, and (H) His-6-tags
2 Fab2-FH-X22-HRP= Bivalent Fab antibody with (F) DYKDDDDK, (H) His-6-tags and Fab-SpyTag coupled to HRP conjugated BiCatcher

Anti-Obinutuzumab Inhibitory Antibodies (Type 1)

Type 1 anti-obinutuzumab antibodies inhibit the binding of the drug obinutuzuamab to its target, the B cell surface marker CD20. They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. The antibody in fully human IgG1 format is suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.

ELISA Protocols to Get You Started

PK Bridging ELISA

PK Bridging ELISA: TZA048 (capture), TZA049P (detection)

Fig. 1. Obinutuzumab PK bridging ELISA using antibodies TZA048 and TZA049P.

Fig. 1. Obinutuzumab PK bridging ELISA using antibodies TZA048 and TZA049P.

Schematic image of PK bridging ELISA measuring free drug.

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Fab format (purple) labeled with HRP.

ADA Bridging ELISA

ADA Bridging ELISA: HCA403, HCA404, HCA405

Fig. 2. Obinutuzumab ADA bridging ELISA using antibody HCA403, HCA404, and HCA405.

Fig. 2. Obinutuzumab ADA bridging ELISA using antibody HCA403, HCA404, and HCA405.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Resources

Anti-idiotypic antibodies, their binding types and properties

Anti-biotherapeutic antibody quality control and characterization

Custom anti-idiotypic antibody generation service

Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.